deltatrials
Approved For Marketing EXPANDED_ACCESS NCT04777734

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Sponsor: argenx

Conditions Generalized Myasthenia Gravis
Interventions efgartigimod
Updated 5 times since 2021 Last updated: Apr 25, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Generalized Myasthenia Gravis and is currently ongoing. argenx leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2021 – ~Mar 2022 · 11 months · monthly snapshotAvailable~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshotApproved For Marketing~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotApproved For Marketing

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Approved For Marketing

  2. Jul 2024 — Sep 2024 [monthly]

    Approved For Marketing

  3. May 2022 — Jul 2024 [monthly]

    Approved For Marketing

    Status: Available → Approved For Marketing

  4. Mar 2022 — May 2022 [monthly]

    Available

  5. Apr 2021 — Mar 2022 [monthly]

    Available

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • argenx
Data source: argenx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations